2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea

Abstract

As in other countries, type 2 diabetes is major health concern in Korea. A dramatic increase in the prevalence of type 2 diabetes and its chronic complications has led to an increase in health costs and economic burdens. Early detection of high risk individuals, hidden diabetic patients, and improvement in the quality of care for the disease are the first steps to mitigate the increase in prevalence. The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the '3rd Clinical Practice Guidelines' at the end of 2010. In the guidelines, the committee recommended active screening of high risk individuals for early detection and added the hemoglobin A1c level to the diagnostic criteria for type 2 diabetes based on clinical studies performed in Korea. Furthermore, the committee members emphasized that integrating patient education and self-management is an essential part of care. The drug treatment algorithm based on the degree of hyperglycemia and patient characteristics were also updated.

Body Mass Index and Waist Circumference According to Glucose Tolerance Status in Korea: The 2005 Korean Health and Nutrition Examination Survey

“…Clinical practice guidelines for type 2 diabetes in Korea 2011 recommended screening methods differently according to stage of IFG (stage 1, FPG 100-109 mg/dL, stage2: FPG 110-125) (25). So we divided our IFG participants into two groups according to above mentioned criteria.…”

Association between flavonoid intake and diabetes risk among the Koreans

“…The 2011 clinical practice guidelines for T2DM in Korea recommend different screening methods according to IFG stage (stage 1, FPG level of 100-109 mg/dl, stage 2, FPG level of 110-125) [14]. Considering that the dataset did not include any personal information and participant consent was already taken obtained in the process of the KNHANES, this study was exempted from obtaining participant consent by the board.…”

Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin–sulfonylurea combination: Results of a multicenter, cross‐sectional, observational study in Korea

“…The international guidelines, including American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) guidelines6, the American Association of Clinical Endocrinologists/American College of Endocrinology Diabetes Guidelines (AACE/ACE) guidelines7 and the Korean national guidelines8, suggest comprehensive management of patients with type 2 diabetes to maintain glycemic control, and reduce the risk of microvascular and macrovascular diabetes-related complications. According to the algorithm for medical management of type 2 diabetes, the ADA/EASD guidelines recommend initial therapy with lifestyle changes and then use of metformin (Met), followed by continuing timely augmentation of therapy with additional agents (including sulfonylureas [SU] and early initiation of insulin therapy)6.…”